Alpha 2 agonists for sedation to produce better outcomes from critical illness (A2B Trial): protocol for a multicentre phase 3 pragmatic clinical and cost-effectiveness randomised trial in the UK

Alpha 2 agonists for sedation to produce better outcomes from critical illness (A2B Trial): protocol for a multicentre phase 3 pragmatic clinical and cost-effectiveness randomised trial in the UK

Introduction Almost all patients receiving mechanical ventilation (MV) in intensive care units (ICUs) require analgesia and sedation. The most widely used sedative drug is propofol, but there is uncertainty whether alpha2-agonists are superior. The alpha 2 agonists for sedation to produce better out...

Full description

Saved in:
Bibliographic Details
Main Authors: John Norrie, Stephen Morris, Daniel Francis McAuley, Bronagh Blackwood, Paul Dark, Matt P Wise, Anthony C Gordon, Kalliopi Kydonaki, Timothy Simon Walsh, David Hope, Christopher Weir, Gavin Perkins, Nazir I Lone, Benedict Creagh-Brown, Julia Boyd, Michael Reade, Richard Anthony Parker, Leanne M Aitken, Valerie J Page, Alasdair MacLullich, Cathrine A McKenzie, Alix Macdonald, Annabel Giddings, Lydia Emerson, Robert Glen
Format: Article
Language:English
Published: BMJ Publishing Group 2023-12-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/13/12/e078645.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://bmjopen.bmj.com/content/13/12/e078645.full

Similar Items